Objective: Invasive fungal infection is one of the major causes of death in neutropenic patients undergoing allogeneic stem cell transplantation (SCT). Although prophylactic antifungal therapy with fluconazole (FLCZ) has become the standard care for these patients, there remains a need for more effective and cost-beneficial alternative drugs.
Introduction
Although the mortality rate in patients with infection occurring early after allogeneic stem cell transplantation (SCT) has been markedly decreased due to the administration of G-CSF and prophylactic use of anti-viral drugs against VZV/HSV and CMV, invasive fungal infection (IFI) still remains a major cause of death. Once IFI has occurred in patients who have received immunosuppressants for prophylaxis or treatment of acute graft-versus-host disease (GVHD), the prognosis is very poor. The incidence of IFI in patients who have undergone allogeneic SCT is higher than that in those who have undergone autologous SCT [1] . For this indication, fluconazole (FLCZ) has been routinely used in many institutions and has shown excellent antifungal effects in both patients who have undergone autologous SCT and allogeneic SCT [2, 3] . However, its use is associated with breakthrough fungal infection in some patients and expensive costs in cases with intravenous administration. Moreover, FLCZ does not protect patients from invasive aspergillosis. In this regard, there is a need for more effective and less expensive alternative drugs in allogeneic SCT.
Micafungin (MCFG) is a novel antifungal agent of the echinocandin class that inhibits the synthesis of 1, 3-β-D-glucan, an essential component of the fungal cell wall [4] . This drug has been demonstrated to exhibit an excellent in vitro activity against both Candida and Aspergillus [4] , and clinical studies have also shown good activity in patients with febrile neutropenia and invasive candidiasis [5, 6] . Moreover, MCFG is also effective against FLCZ-resistant Candida albicans. Azoles other than FLCZ have serious drug-to-drug interaction effects through the cytochrome P450 3A4 pathway, and so the use of other azoles in allogeneic SCT is therefore difficult. Moreover, although FLCZ has few side effects, itraconazole (ITCZ) and voriocnazole (VRCZ) usually have gastrointestinal or visual side effects. For these reasons, we considered MCFG to be a potential alternative to FLCZ, and we performed a prospective study to evaluate the usefulness of MCFG in prophylactic therapy for neutropenic patients undergoing allogeneic SCT.
Patients and Methods

Study design
This was a prospective study conducted in a single institution. The major objective of this study was to evaluate the efficacy, feasibility, and cost-benefit of prophylactic therapy with MCFG for patients undergoing allogeneic SCT. The primary end point was treatment success, which was defined as the absence of proven, probable, or possible IFI until day 21 after the SCT. The secondary end point was the absence of proven or probable IFI until day 49 after the SCT [7] . Types of IFI were defined by the European Organization for Research and Treatment of Cancer/Mycology Study Group (EORTC/MSG) criteria [8] . After obtaining written informed consent, patients were treated according to the protocol. The protocol was reviewed and approved by the Institutional Review Board. The data obtained from this study were compared with historical data from patients who received prophylactic FLCZ at 400 mg/day before the start of this study.
Patients
Adult patients with hematological and non-hematological malignancy undergoing allogeneic SCT were eligible for the study if they did not have significant hepatic or renal dysfunctions (defined as a level of bilirubin, ALT, AST, or creatinine that was less than two times the upper limit of the normal range). Patients were excluded if they had a previous history of allergy to MCFG or active IFI at the time of enrollment. Patients receiving antifungal prophylaxis with other drugs were allowed to participate; however, administration of any other antifungal drug used had to be discontinued at the time when treatment with MCFG was started. All patients were isolated in a room equipped with a laminar airflow system and had a central venous catheter. All patients were given oral levofloxacin at a daily dose of 300 mg for bacterial prophylaxis, which was also begun 14 days before the transplantation.
Treatment protocol
After enrollment, prophylactic MCFG was started at a daily dose of 100 mg (14, 014 Japanese yen) once a day intravenously over 1 hour from 14 days before allogeneic SCT.
The dose of MCFG was increased to 150~300 mg as the treatment dose or MCFG was changed to another antifungal drug when patients were suspected of having febrile neutropenia or IFI. Therapy was continued until the patient had achieved hematological engraftment (defined as an absolute neutrophil count of over 500/µl after the nadir) and was able to take medicine. After the discontinuation of MCFG, FLCZ was administered orally at 200 mg/day until the cessation of immunosuppressants.
Historical control patients were administered FLCZ at 400 mg/day orally or intravenously (19,908 Japanese yen) starting 14 days before allogeneic SCT, and the dose was decreased to 200 mg orally when the patient had achieved hematological engraftment and was able to take medicine. In cases with possible, probable, or proven IFI, FLCZ was changed to another antifungal drug.
Clinical and laboratory evaluations
Patients were monitored daily for clinical signs and symptoms. Analysis of complete blood counts and chemistry parameters was performed at least 3 times a week.
Surveillance cultures were obtained from the throat, urine, and stools once a week throughout the study period. Blood cultures and chest X-rays were performed when the patients suffered from fever up to 37.5 . Serum β-D-glucan and Aspergillus-antigen (galactomannan) were checked once a week during the study. CT scanning was performed in patients with suspected pulmonary infections. Adverse events were graded on the basis of the National Cancer Institute Common Toxicity Criteria version 2.0.
Statistical analysis
Fisher's exact test and Student's t-test were used for analysis. All comparisons were 2-sided, with a significance level of 5%.
Results
Patients
Between January 2004 and March 2007, a total of 44 patients were enrolled in the MCFG group. Data for 29 historical cases treated with FLCZ were also analyzed. Clinical characteristics of the patients are listed in Table 1 . Underlying diseases included acute leukemia (n=16), non-Hodgkin's lymphoma (n=11), myelodysplastic syndrome (n=6), and others (n=11) in the MCFG group and acute leukemia (n=18), chronic myelogenous leukemia (n=6), and others (n=5) in the FLCZ group. Two patients in the MCFG group had a past history of IFI. Baseline fungal infections defined by EORTC/MSG criteria were absent in all patients before starting MCFG or FLCZ treatment. The median age of patients in the MCFG group was more advanced than that of patients in the FLCZ group (p=0.006). Rates of non-myeloablative conditioning and tacrolimus for acute GVHD prophylaxis were higher in the MCFG group (p=0.00006 and p=0.044, respectively). The median day of engraftment was day 15 in both groups (data not shown). Therefore, durations of neutropenia (until day 15 after the SCT) in the two groups were similar. The numbers of cases with grade II to IV acute GVHD that needed prednisolone (PSL) administration were 10 in the MCFG group and 4 in the FLCZ group (p=0.3680) ( Table   1 ).
Treatment and efficacy
MCFG was given to 44 patients for prophylaxis. The initial dose for 42 patients was 100 mg. Treatment was started at a dose of 150 mg in two patients because of a previous history of IFI. The dose was increased to 150 mg in four patients because of febrile neutropenia, but there was no case requiring dose reduction due to adverse effects. FLCZ was given to 29 patients. In one patient, the dose was increased from 200 to 400 mg, but treatment with FLCZ was started at a dose of 400 mg in the other 28 patients. The median duration of administration of MCFG was 36 days (range: 11 to 80 days) and that of FCLZ was 34 days (range: 14 to 114 days) ( Table 2) . (Table 3 ). In this study, there was no significant risk factor in the patient characteristics other than the administration of MCFG or FLCZ.
Toxicity
Skin rash of grade 2 developed soon after administration in one patient in the MCFG group. Hepatic dysfunction of grade 2 and elevation of creatinine of grade 1 were observed in the FCLZ group.
Discussion
The beneficial role of FLCZ in patients undergoing allogeneic SCT was documented in a previous report [9] . However, its use was costly because most patients suffered from severe stomatitis and required the intravenous administration of FLCZ instead of oral capsules. Moreover, the rates of treatment success of FLCZ in allogeneic SCT settings are 68 to 81% [7, 10, 11] . One of the major concerns about the use of FLCZ is its lack of activity against Aspergillus species and some non-albicans Candida species. An increasing prevalence of such resistant strains has been reported, primarily due to the widespread use of prophylactic FLCZ [12, 13, 14] . Moreover, the incidence of aspergillosis in patients undergoing allogeneic SCT has been reported to be increasing, even in a bio-clean room equipped with laminar airflow [15] . Recently, several studies have shown that the incidence of invasive aspergillosis was higher in patients treated with non-myeloablative conditioning, who are administered stronger immunosuppressants than those in patients receiving myeloablative conditioning [16, 17] . Moreover, FLCZ inhibits the activity of hepatic cytochrome P450 3A4, as do other azoles, resulting in increased serum concentrations of cyclosporine A and tacrolimus. Therefore, less expensive, more effective, and safer alternative drugs are needed.
Recently, lipid formulations of AMPH-B have been shown to be equivalent to conventional AMPH-B in terms of efficacy, with less nephrotoxicity and infusion-related reactions. However, its routine use is limited due to its high cost. The use of oral ITCZ is also limited because of the wide ranging bioavailability of the capsule form and the adverse gastrointestinal effects of the oral solution.
MCFG, similar to caspofungin, is an echinoicandin agent that targets fungal cell walls.
In vitro and in vivo studies have shown that it has a broad spectrum and strong activity with fewer adverse effects in patients with candidaemia and invasive candidiasis [4, 6] .
There is only one report of MCFG being used as prophylaxis in allogeneic SCT [7] .
Although the number of patients in the present study was limited and the protocol design was not a randomized prospective study, this is the first study showing that administration of MCFG at a daily dose of 100 mg as prophylactic antifungal therapy in patients undergoing allogeneic SCT resulted in the prevention of proven and probable IFI.
Compared with the results of previous studies, ours are encouraging.
It is also notable that none of the patients except one required discontinuation or dose reduction of the drug due to adverse events. Both MCFG and FLCZ were generally well tolerated.
The major problem lies in the diagnostic uncertainty of fungal infections. It is difficult to obtain a proven diagnosis of IFI before autopsy because of the difficulty in tissue biopsy due to neutropenia and severe thrombocytopenia. Since Hofmeister et al. reported that analysis of bronchoalveolar lavage or transbronchial biopsy did not lead to any survival benefit from an addition to the treatment regimen after a positive result, such invasive diagnostic procedures may be replaced by serological and radiological examinations [18] . In order to solve this problem, the EORTC/MSG criteria have recently been proposed [8] . However, since these criteria have not been used in most previous studies, we could not make a strict comparison with historical data. Frequent serological examinations for IFI using different methods, including 1-3β-D-glucan and galactomannan antigenemia, are important for early diagnosis. Marr et al. reported that the use of a cutoff index of galactomannan reduced to 0.5 facilitated a more specific diagnosis of aspergillosis [19] .
An optimal treatment design of MCFG in patients undergoing allogeneic SCT is also a problem to be solved. When we started this study, there was little information on optimal treatment, and we therefore used a slightly higher dose than that employed in a previous study [7] . A lower dose of MCFG (50 mg) is now allowed by the Health Insurance System in Japan for IFI prophylaxis; however, further investigation is needed to determine the optimal dose. Although the feasibility of persistent protection by FLCZ has been described in one report, the optimal duration of prophylaxis also remains uncertain for patients who are administered immunosuppressants for a long time, especially in cases with non-myeloablative cord blood transplantation [9] . Although several authors have reported that acute GVHD and the administration of PSL were risk factors for invasive aspergillosis, our study did not show such a relationship because of the small number of patients, as Winston et al. reported previously [11, 14, 20] . Although a long neutropenic period is also a risk factor for IFI, the difference between neutropenic periods in the two groups in this study was not significant. Moreover, two breakthrough definitive fungal infections in the patients receiving FLCZ occurred early after HSCT. Therefore, the difference in prophylactic efficacy was not due to a difference in the neutropenic period.
In summary, although this study was not a prospective randomized study and the number of enrolled patients was small, the results of our clinical trial demonstrated that MCFG administered to allogeneic SCT patients at a daily dose of 100 mg was able to completely prevent both probable and proven IFI and was superior to FLCZ in overall efficacy. Marr et al. reported that not short-term but prolonged FLCZ prophylaxis was associated with persistent protection against candidiasis-related death in patients undergoing allogeneic SCT, and that the median day of onset of IFI after engraftment in cord blood transplantation is day 100 [9, 21] . Therefore, the effects and safety of the prolonged administration of antifungal drugs may be the next area of investigation. NS, not significant. 
